Daré Bioscience Statistics
Total Valuation
Daré Bioscience has a market cap or net worth of $26.58 million. The enterprise value is $6.44 million.
Important Dates
The last earnings date was Thursday, November 13, 2025, after market close.
| Earnings Date | Nov 13, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Daré Bioscience has 14.29 million shares outstanding. The number of shares has increased by 15.58% in one year.
| Current Share Class | 14.29M |
| Shares Outstanding | 14.29M |
| Shares Change (YoY) | +15.58% |
| Shares Change (QoQ) | +43.78% |
| Owned by Insiders (%) | 0.97% |
| Owned by Institutions (%) | 7.19% |
| Float | 11.63M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | -465.22 |
| Forward PS | 2.89 |
| PB Ratio | 9.07 |
| P/TBV Ratio | 9.30 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.18, with a Debt / Equity ratio of 1.03.
| Current Ratio | 1.18 |
| Quick Ratio | 1.11 |
| Debt / Equity | 1.03 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -2,543.13% and return on invested capital (ROIC) is -382.46%.
| Return on Equity (ROE) | -2,543.13% |
| Return on Assets (ROA) | -44.74% |
| Return on Invested Capital (ROIC) | -382.46% |
| Return on Capital Employed (ROCE) | -183.27% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$759,302 |
| Employee Count | 23 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -51.50% in the last 52 weeks. The beta is 0.77, so Daré Bioscience's price volatility has been lower than the market average.
| Beta (5Y) | 0.77 |
| 52-Week Price Change | -51.50% |
| 50-Day Moving Average | 2.06 |
| 200-Day Moving Average | 2.58 |
| Relative Strength Index (RSI) | 41.07 |
| Average Volume (20 Days) | 109,668 |
Short Selling Information
The latest short interest is 221,779, so 1.55% of the outstanding shares have been sold short.
| Short Interest | 221,779 |
| Short Previous Month | 185,018 |
| Short % of Shares Out | 1.55% |
| Short % of Float | 1.91% |
| Short Ratio (days to cover) | 1.22 |
Income Statement
In the last 12 months, Daré Bioscience had revenue of -$57,130 and -$17.46 million in losses. Loss per share was -$1.82.
| Revenue | -57,130 |
| Gross Profit | -14.35M |
| Operating Income | -17.47M |
| Pretax Income | -17.46M |
| Net Income | -17.46M |
| EBITDA | -16.36M |
| EBIT | -17.47M |
| Loss Per Share | -$1.82 |
Full Income StatementBalance Sheet
The company has $23.08 million in cash and $2.93 million in debt, giving a net cash position of $20.14 million or $1.41 per share.
| Cash & Cash Equivalents | 23.08M |
| Total Debt | 2.93M |
| Net Cash | 20.14M |
| Net Cash Per Share | $1.41 |
| Equity (Book Value) | 2.86M |
| Book Value Per Share | 0.21 |
| Working Capital | 3.79M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$6.10 million and capital expenditures -$741,486, giving a free cash flow of -$6.85 million.
| Operating Cash Flow | -6.10M |
| Capital Expenditures | -741,486 |
| Free Cash Flow | -6.85M |
| FCF Per Share | -$0.48 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | 30,578.09% |
| Pretax Margin | 30,568.80% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Daré Bioscience does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -15.58% |
| Shareholder Yield | -15.58% |
| Earnings Yield | -65.71% |
| FCF Yield | -25.75% |
Analyst Forecast
The average price target for Daré Bioscience is $10.00, which is 437.63% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $10.00 |
| Price Target Difference | 437.63% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (5Y) | 678.66% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on July 1, 2024. It was a reverse split with a ratio of 1:12.
| Last Split Date | Jul 1, 2024 |
| Split Type | Reverse |
| Split Ratio | 1:12 |
Scores
Daré Bioscience has an Altman Z-Score of -9.68 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -9.68 |
| Piotroski F-Score | 3 |
